SION
Sionna TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-04
Current thesis
The bull case is concentrated in two summer 2026 clinical readouts, with company-reported cash and cash equivalents of approximately $289.9 million expected to fund operations into 2028. [#SEC-8K-2026-05-12]
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical development spending and losses can erode runway despite the company’s stated expectation that cash funds operations into 2028. [#PR-EARNINGS-2026-05-12]
Momentum
81
Value
46
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $48.00 · Bull $67.00 · Bear $30.00
Data freshness
Prices
As of 2026-08-04
Fundamentals
As of 2026-08-04 • Vendor: Data Vendor v1
Scores
As of 2026-08-04 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-04
Investment thesis
As of 2026-08-04
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $51.60
Why
Momentum81 · Δ7d +9.9
Value46 · Δ7d -0.0
Sentiment51 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
81
10% active weight
Current posture
7d trendSoftening
Δ7d
+9.9
Δ21d
+21.9
Value
46
40% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.0
Sentiment
51
49% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 80.9 / Value 46.4 / Sentiment 51.3
Fundamentals (TTM)As of 2026-08-04
Fundamentals (TTM)
As of 2026-08-04
Market Cap
$2.25B
Beta
-
Shares Out
45.15M
P/E (TTM) · Derived
-29.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-30.89
Rev YoY
-
EPS YoY
+58.9%
Gross Margin
-
Op Margin
-
Net Debt
-$227.21M
Current Ratio
22.60
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology